Literature DB >> 28890641

Pharmaceutical Approval Update.

Michele B Kaufman.   

Abstract

Sarilumab (Kevzara) for moderately to severely active rheumatoid arthritis; valbenazine (Ingrezza), the first approval for tardive dyskinesia; and cerliponase alpha (Brineura) for late infantile neuronal ceroid lipofuscinosis type-2 disease.

Entities:  

Year:  2017        PMID： 28890641      PMCID： PMC5565128     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  2 in total

Review 1.  Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.

Authors:  Niyanta N Kumar; Michelle E Pizzo; Geetika Nehra; Brynna Wilken-Resman; Sam Boroumand; Robert G Thorne
Journal:  Bioconjug Chem       Date:  2018-10-24       Impact factor: 4.774

Review 2.  [Neuroinflammation in neuronal ceroid lipofuscinosis].

Authors:  V Behnke; T Langmann
Journal:  Ophthalmologe       Date:  2021-01-07       Impact factor: 1.059
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.